Ipsen

Ipsen is the core company node behind Dysport, a botulinum toxin type A product with the nonproprietary name abobotulinumtoxinA. Dysport gives Ipsen a durable position in therapeutic toxin use and in aesthetic-market comparison conversations.

Ipsen’s role should be separated from Galderma. Ipsen remains central to Dysport’s product origin, registered trademark context, and therapeutic franchise, while Galderma commercializes Dysport-family aesthetic products in licensed territories. Those roles are related, but they are not the same answer to every “who makes Dysport” or “who owns Dysport” question.

Quick Answers

Question	Short answer
Who makes Dysport?	Ipsen is the core product-origin and company node for Dysport / abobotulinumtoxinA. Galderma commercializes aesthetic Dysport-family products in licensed territories.
Who owns Dysport?	A precise answer depends on the role being asked about: product origin and registered trademark context point to Ipsen, while aesthetic commercialization rights in licensed markets point to Galderma.
Is Dysport a Galderma product?	Galderma is an important aesthetic commercialization partner, but Dysport should not be described as simply manufactured by Galderma.
What is Azzalure?	Azzalure is a Dysport-family aesthetic brand name used in some markets; it should be interpreted through local approval and product information.
What is Alluzience?	Alluzience is another Dysport-family aesthetic product commercialized by Galderma where approved; it should not be treated as a U.S. Dysport label.
Are Dysport units comparable with Botox or Xeomin units?	No. Dysport units are product-specific and should not be directly converted into units of other botulinum toxin products.

Reference Card

Field	Reference point
Company	Ipsen
Base	France
Website	ipsen.com 🔗
Public status	Euronext Paris-listed
Core toxin relationship	Botulinum toxin type A product family centered on abobotulinumtoxinA
Main brand node	Dysport
Product identity	Dysport is abobotulinumtoxinA
Key commercialization relationship	Galderma commercializes Dysport / Azzalure / Alluzience for aesthetic use in licensed territories, while Ipsen retains the core product and therapeutic-franchise context.
Market role	Longstanding multinational comparison anchor for therapeutic and aesthetic type A products
Comparison anchors	Botox, Xeomin, Daxxify, Letybo, Jeuveau

Person	Why the relationship matters
Olivia Brown	Executive Vice President, Global Head of Neurotoxins, useful for connecting Ipsen’s current Dysport / neurotoxins franchise leadership to therapeutic and aesthetic-market strategy.
Christelle Huguet	Executive Vice President, Head of R&D, useful for separating Ipsen’s broader neuroscience and development organization from the marketed Dysport franchise.
Peter Hambleton, Ph.D.	CAMR and Porton Down researcher whose therapeutic-toxin production work helps explain the development pathway preceding the current Dysport / Ipsen structure.

Dysport Manufacturer, Owner, And Galderma Relationship

Dysport is the primary botulinum toxin product represented by Ipsen in the current site structure. Ipsen’s U.S. product listing identifies Dysport as abobotulinumtoxinA and states that Dysport is a registered trademark of Ipsen Biopharm Limited.

Galderma adds a separate commercialization layer. Galderma has described its role as continuing to commercialize and supply Dysport, Azzalure, and Alluzience in territories where approved and under the relevant commercial agreements. That role is important for aesthetic market access, but it does not erase Ipsen’s product-origin and therapeutic-company context.

Relationship question	Best answer	Important limit
Product-origin company	Ipsen	Product origin does not make every regional brand name share one label.
U.S. therapeutic product listing	Ipsen	A therapeutic label should not be transferred to aesthetic products or other markets.
Aesthetic commercialization in licensed territories	Galderma	Commercialization rights do not make Galderma the universal manufacturer or owner for every Dysport presentation.

Dysport, Azzalure, And Alluzience Naming

Dysport is the central brand name in the site graph because it anchors the abobotulinumtoxinA product family in U.S. and international comparison discussions. Azzalure and Alluzience matter because they show how the same broader product family can appear through different aesthetic-market names and presentations.

That naming map should not be read as a single universal approval. Dysport, Azzalure, and Alluzience remain tied to local labels, approved indications, presentations, and availability.

Market Interpretation

Ipsen helps define the competitive structure of the established global type A market. Dysport is not merely a secondary brand in the Botox comparison conversation; it has its own product history, label language, and clinical evidence base.

At the same time, company-level importance should not be translated into a claim of clinical superiority. The safest comparison path is Dysport label first, then local market context, then carefully sourced evidence.

Label and Comparison Limits

U.S. Dysport interpretation should use current prescribing information. Regional product information may differ, and a familiar use in one country should not be treated as a universal Dysport approval.

The Dysport unit system is a central caution point. Larger numeric unit amounts do not mean that Dysport can be converted directly into Botox, Xeomin, Jeuveau, Daxxify, Letybo, or any other toxin product.

Botulinum toxin type A supplies the shared serotype context. Type A vs type B helps separate Dysport from type B products such as Myobloc / Neurobloc.